RESUMEN
Balo's concentric sclerosis (BCS) is considered a rare variant of multiple sclerosis, which often mimics an intracranial neoplasm or abscess. We report the case of a 21-year-old woman presenting with BCS while undergoing treatment for pulmonary tuberculosis. Initial brain magnetic resonance imaging (MRI) findings were similar to those for cerebral tuberculoma, multiple metastases, or abscesses. However, the pathognomonic concentric sclerosis characteristic of BCS was seen on MRI. The antemortem confirmatory diagnosis of BCS was made by follow-up MRI and a brain biopsy. It is suggested that BCS should be included in the differential diagnosis of cerebral tuberculoma, especially in developing countries with a high prevalence of tuberculosis.
Asunto(s)
Femenino , Humanos , Adulto Joven , Absceso , Corticoesteroides , Biopsia , Encéfalo , Neoplasias Encefálicas , Países en Desarrollo , Diagnóstico , Diagnóstico Diferencial , Esclerosis Cerebral Difusa de Schilder , Estudios de Seguimiento , Imagen por Resonancia Magnética , Esclerosis Múltiple , Metástasis de la Neoplasia , Prevalencia , Esclerosis , Tuberculoma , Tuberculosis , Tuberculosis PulmonarRESUMEN
Oxcarbazepine (OXC) is generally assumed to be safe with regard to the risk for adverse hematopoietic effects. Recently, pancytopenia and leukopenia associated with the treatment of OXC have been reported. However, that serious adverse effect has never been reported in Korea. We describe a case of 47-year-old woman with temporal lobe epilepsy who developed reversible leukopenia following OXC monotherapy. She stopped to take OXC and WBC count was normalized completely.
Asunto(s)
Femenino , Humanos , Carbamazepina , Epilepsia del Lóbulo Temporal , Corea (Geográfico) , Leucopenia , PancitopeniaRESUMEN
Oxcarbazepine (OXC) is generally assumed to be safe with regard to the risk for adverse hematopoietic effects. Recently, pancytopenia and leukopenia associated with the treatment of OXC have been reported. However, that serious adverse effect has never been reported in Korea. We describe a case of 47-year-old woman with temporal lobe epilepsy who developed reversible leukopenia following OXC monotherapy. She stopped to take OXC and WBC count was normalized completely.